| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802857102016 | 285710201 | GRANISETRON/SPECIFAR F.C.TAB 2MG/TAB BTx5 (σε BLISTERS) | 19.30 | 20.25 | 27.91 |
For the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
Granisetron is a potent, selective antagonist of 5-HT<sub>3</sub> receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
LD<sub>50</sub>&gt;2000 mg/kg (rat, oral)
Absorption of is rapid and complete, though oral bioavailability is reduced to about 60% as a result of first pass metabolism.
4-6 hours in healthy patients, 9-12 hours in cancer patients
The remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.
* 0.52 L/h/kg [Cancer Patients with 1 mg bid for 7 days] * 0.41 L/h/kg [Healthy subject with a single 1 mg dose]